These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 35546777)
1. A Review on Acridines as Antiproliferative Agents. Baliwada A; Rajagopal K; Varakumar P; Raman K; Byran G Mini Rev Med Chem; 2022; 22(21):2769-2798. PubMed ID: 35546777 [TBL] [Abstract][Full Text] [Related]
2. A new look at 9-substituted acridines with various biological activities. Kozurkova M; Sabolova D; Kristian P J Appl Toxicol; 2021 Jan; 41(1):175-189. PubMed ID: 32969520 [TBL] [Abstract][Full Text] [Related]
3. Novel 3,9-Disubstituted Acridines with Strong Inhibition Activity against Topoisomerase I: Synthesis, Biological Evaluation and Molecular Docking Study. Krochtová K; Halečková A; Janovec L; Blizniaková M; Kušnírová K; Kožurková M Molecules; 2023 Jan; 28(3):. PubMed ID: 36770975 [TBL] [Abstract][Full Text] [Related]
4. Fluorinated 3,6,9-trisubstituted acridine derivatives as DNA interacting agents and topoisomerase inhibitors with A549 antiproliferative activity. Nunhart P; Konkoľová E; Janovec L; Jendželovský R; Vargová J; Ševc J; Matejová M; Miltáková B; Fedoročko P; Kozurkova M Bioorg Chem; 2020 Jan; 94():103393. PubMed ID: 31679839 [TBL] [Abstract][Full Text] [Related]
5. Acridine derivatives as inhibitors/poisons of topoisomerase II. Kozurkova M J Appl Toxicol; 2022 Apr; 42(4):544-552. PubMed ID: 34514603 [TBL] [Abstract][Full Text] [Related]
6. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome. Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647 [TBL] [Abstract][Full Text] [Related]
7. Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II. Oppegard LM; Ougolkov AV; Luchini DN; Schoon RA; Goodell JR; Kaur H; Billadeau DD; Ferguson DM; Hiasa H Eur J Pharmacol; 2009 Jan; 602(2-3):223-9. PubMed ID: 19071108 [TBL] [Abstract][Full Text] [Related]
8. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Finlay GJ; Riou JF; Baguley BC Eur J Cancer; 1996 Apr; 32A(4):708-14. PubMed ID: 8695277 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and antiproliferative activity of 9-benzylamino-6-chloro-2-methoxy-acridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors. Zhang W; Zhang B; Zhang W; Yang T; Wang N; Gao C; Tan C; Liu H; Jiang Y Eur J Med Chem; 2016 Jun; 116():59-70. PubMed ID: 27060757 [TBL] [Abstract][Full Text] [Related]
10. [The structural and functional analysis of the biological activity of acridine derivatives]. Deeva EG; Pavlovskaia IaV; Kiselev OI; Kiselev VI; Piotrovskiĭ LB; Ershov FI Vestn Ross Akad Med Nauk; 2004; (2):29-34. PubMed ID: 15101206 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of DNA topoisomerases I and II and growth inhibition of HL-60 cells by novel acridine-based compounds. Janočková J; Plšíková J; Kašpárková J; Brabec V; Jendželovský R; Mikeš J; Kovaľ J; Hamuľaková S; Fedoročko P; Kuča K; Kožurková M Eur J Pharm Sci; 2015 Aug; 76():192-202. PubMed ID: 25960253 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of acridine- and acridone-based anti-herpes agents with topoisomerase activity. Goodell JR; Madhok AA; Hiasa H; Ferguson DM Bioorg Med Chem; 2006 Aug; 14(16):5467-80. PubMed ID: 16713270 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors. Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683 [TBL] [Abstract][Full Text] [Related]
14. New spiro tria(thia)zolidine-acridines as topoisomerase inhibitors, DNA binders and cytostatic compounds. Salem OM; Vilková M; Janočková J; Jendželovský R; Fedoročko P; Žilecká E; Kašpárková J; Brabec V; Imrich J; Kožurková M Int J Biol Macromol; 2016 May; 86():690-700. PubMed ID: 26861825 [TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents. Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479 [TBL] [Abstract][Full Text] [Related]
16. Acridine as an Anti-Tumour Agent: A Critical Review. Varakumar P; Rajagopal K; Aparna B; Raman K; Byran G; Gonçalves Lima CM; Rashid S; Nafady MH; Emran TB; Wybraniec S Molecules; 2022 Dec; 28(1):. PubMed ID: 36615391 [TBL] [Abstract][Full Text] [Related]
17. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883 [TBL] [Abstract][Full Text] [Related]
18. Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα. Infante Lara L; Sledge A; Laradji A; Okoro CO; Osheroff N Bioorg Med Chem Lett; 2017 Feb; 27(3):586-589. PubMed ID: 27998679 [TBL] [Abstract][Full Text] [Related]
19. Substituted benz[a]acridines and benz[c]acridines as mammalian topoisomerase poisons. Makhey D; Yu C; Liu A; Liu LF; LaVoie EJ Bioorg Med Chem; 2000 May; 8(5):1171-82. PubMed ID: 10882027 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors. Li D; Yuan Z; Chen S; Zhang C; Song L; Gao C; Chen Y; Tan C; Jiang Y Bioorg Med Chem; 2017 Jul; 25(13):3437-3446. PubMed ID: 28511910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]